Phathom Pharmaceuticals (PHAT) EBITDA (2018 - 2026)

Phathom Pharmaceuticals (PHAT) has 9 years of EBITDA data on file, last reported at -$15.5 million in Q1 2026.

• On a quarterly basis, EBITDA rose 80.37% year-over-year to -$15.5 million in Q1 2026; TTM through Mar 2026 was -$96.6 million, a 66.27% increase from a year earlier, with the FY2025 full-year figure at -$160.0 million, up 42.34% from the prior year.
• EBITDA for Q1 2026 stood at -$15.5 million, down from -$5.9 million in the prior quarter.
• Over the last five years, EBITDA for PHAT reached as high as -$5.9 million in Q4 2025 and fell as low as -$78.9 million in Q1 2025.
• Historically, EBITDA has averaged -$46.6 million across 5 years, with a median of -$45.4 million in 2022.
• Across the five-year window, EBITDA tumbled 143.84% in 2024 and soared 90.02% in 2025, its largest moves.
• Year by year, EBITDA stood at -$46.6 million in 2022, then sank by 49.81% to -$69.9 million in 2023, then advanced by 14.97% to -$59.4 million in 2024, then surged by 90.02% to -$5.9 million in 2025, then tumbled by 161.08% to -$15.5 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$15.5 million in Q1 2026, -$5.9 million in Q4 2025, and -$15.3 million in Q3 2025.